Jun 20, 2024, 11:53
Mohamad Mohty shares long-term survival outcomes from the phase II MagnetisMM-3 study – Multiple Myeloma Hub
Multiple Myeloma Hub shared on X/Twitter:
“CONGRESS | POSTER | EHA2024 | Mohamad Mohty shares long-term survival outcomes from the phase II MagnetisMM-3 study of elranatamab in patients with RRMM, N=123. ORR remained at 61%, with median DoR not reached.”
Source: Multiple Myeloma Hub/X